← Back to Search

Virus Vaccine

Seasonal Influenza Vaccines for Flu

Phase 4
Recruiting
Led By James J Kobie, PhD
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18-50 years old for Arm 1 and Arm 2
Weight of at least 110 lbs as determined by self-reporting
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months after vaccination
Awards & highlights

Study Summary

This trial will look at how well different types of flu vaccines work in people of different ages, and whether previous vaccinations affect immunity.

Who is the study for?
This trial is for healthy adults aged 18-50 and 65-80 who can consent to participate. They must weigh at least 110 lbs and not have a history of severe illnesses, recent heart attacks, strokes, or certain chronic diseases like dementia or lupus. Pregnant women, those with egg allergies, bleeding disorders, drug abuse issues (excluding marijuana), or immunodeficiencies are excluded.Check my eligibility
What is being tested?
The study tests how different FDA-approved flu vaccines—Flucelvax, Fluzone High-Dose, Fluzone, Fluad—affect antibody responses in younger and older adults. It also looks at the impact of past vaccinations on these responses.See study design
What are the potential side effects?
Common side effects from flu vaccines may include soreness at the injection site, headache, feverish feelings or fever itself; muscle aches; fatigue; allergic reactions are rare but can be serious.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 50 years old.
Select...
I weigh at least 110 lbs.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months after vaccination
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months after vaccination for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Hemagglutinin antibody
Neuraminidase antibody
Secondary outcome measures
Hemagglutinin
Neuraminidase Memory B cell ELISPOT Response

Trial Design

5Treatment groups
Active Control
Group I: Fluzone YoungerActive Control1 Intervention
10 adults 18-50 years old, will receive a single dose of the Fluzone influenza vaccine each year for two sequential years
Group II: FlucelvaxActive Control1 Intervention
10 adults 18-50 years old, will receive a single dose of the Flucelvax influenza vaccine each year for two sequential years
Group III: Fluzone OlderActive Control1 Intervention
10 adults 65-80 years old, will receive a single dose of the Fluzone influenza vaccine
Group IV: Fluzone High DoseActive Control1 Intervention
10 adults 65-80 years old, will receive a single dose of the Fluzone High-Dose influenza vaccine
Group V: FluadActive Control1 Intervention
10 adults 65-80 years old, will receive a single dose of the Fluad influenza vaccine

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,590 Previous Clinical Trials
2,281,304 Total Patients Enrolled
James J Kobie, PhDPrincipal InvestigatorUniversity of Alabama at Birmingham

Media Library

Fluad (Virus Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT04101838 — Phase 4
Influenza Research Study Groups: Fluzone Younger, Flucelvax, Fluzone Older, Fluzone High Dose, Fluad
Influenza Clinical Trial 2023: Fluad Highlights & Side Effects. Trial Name: NCT04101838 — Phase 4
Fluad (Virus Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04101838 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who is eligible to partake in this scientific research?

"This study is recruiting 50 individuals with the flu, ranging in age from 18 to 80. To be eligible they must have self-reported weight of at least 110 lbs and participation in ancillary research studies. Arm 1 and 2 are open to those between 18-50 while Arms 3, 4, and 5 accept participants aged 65-80."

Answered by AI

Does this scientific inquiry have any precedent?

"At the moment, 16 clinical trials for Fluzone Younger are running in 17 cities and 16 countries. Initially launched by Pharmacyclics LLC back in 2016 with 42 participants, this drug has since gone on to complete Phase 2 approval as part of 166 studies conducted up until now."

Answered by AI

Are there still opportunities for people to participate in this clinical trial?

"Correct. According to the information posted on clinicaltrials.gov, this medical study that was initially published April 1st 2021 is currently recruiting patients. Fifty participants are sought from a single site."

Answered by AI

Does this research trial extend to individuals beyond the age of eighty-five?

"This trial is accepting participants who are aged 18 and above, up to 80 years old."

Answered by AI

Has Fluzone Younger been approved by the Food and Drug Administration?

"Our estimation at Power is that Fluzone Younger scores a 3 on the safety scale, as Phase 4 trials have already proven its efficacy and approval."

Answered by AI

Could you elaborate on past experiments conducted using Fluzone Younger?

"Presently, Bethesda, Maryland is home to two Phase 3 clinical trials for Fluzone Younger with a total of 16 studies being conducted. Across the United States there are 72 different sites that are involved in these investigations."

Answered by AI

To what extent is the population being observed in this research project?

"Affirmative. The information shared on clinicaltrials.gov verifies that this trial is currently accepting new participants, with the posting date beginning on April 1st 2021 and last updated May 26th 2022. 50 people are needed at one centre for enrolment in this research program."

Answered by AI

Who else is applying?

What state do they live in?
Alabama
What site did they apply to?
University of Alabama at Birmingham
What portion of applicants met pre-screening criteria?
Did not meet criteria
~0 spots leftby May 2024